Comparing Strategies to Introduce Two New Antibiotics for Gonorrhea: A Modeling Study

Madeleine C. Kline[1,2,3], Kirstin Oliveira Roster[1,2], David Helekal[1,2], Eva Rumpler[2,3], Yonatan H. Grad[1,2,3]

1. Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA
2. Center for Communicable Disease Dynamics, Harvard T.H. Chan School of Public Health, Boston, MA, USA
3. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA

Corresponding Author:
Yonatan H. Grad
Harvard T.H. Chan School of Public Health
665 Huntington Ave
Boston, MA 02115
617-432-2275
ygrad@hsph.harvard.edu

Summary: Immediately introducing two new antibiotics to treat gonorrhea alongside one currently used therapy is more effective at minimizing drug resistance than holding the new drugs in reserve.

ABSTRACT

Introduction

Drug resistance in *Neisseria gonorrhoeae* is an urgent public health threat. The anticipated approval of two new antimicrobials for gonorrhea prompts the need for evidence-based rollout strategies that minimize drug resistance.

Methods

We used a stochastic compartmental model of men who have sex with men (MSM) in the United States (U.S.) to compare two main strategies—equal allocation and sequential drug deployment—for two new and one existing drug and measured the time for each drug to reach a resistance prevalence threshold of 5%. We conducted broad analyses assessing the sensitivity of our results to wide variation in parameters governing the baseline behavior of the model and drug resistance evolution and fitness.

Results

Compared to the equal allocation strategy, the sequential strategy had reached the resistance prevalence threshold i) for each drug individually in at least as many simulations; ii) for all three drugs in at least as many simulations; and iii) for at least as many drugs on average. After 10 years, no equal allocation strategy simulations had met the 5% resistance prevalence threshold for any of the drugs, whereas 99.6% of sequential simulations had for the first drug, of which 3.5% had also met the threshold for the second drug. The sequential strategy was worse for nearly every reasonable combination of model parameters.

Conclusion

In a model of U.S. MSM, the equal allocation strategy for introducing new drugs for gonorrhea matched or outperformed the strategy of sequential introduction in terms of resistance prevalence.

INTRODUCTION

The burden of disease caused by *Neisseria gonorrhoeae* and the emergence of extremely drug-resistant strains highlights the need for evidence to optimize treatment options. *N. gonorrhoeae* is an obligate human bacterial pathogen that causes the sexually transmitted infection (STI) gonorrhea. There were an estimated 82.4 million gonorrhea infections worldwide in 2020 and over half a million in the United States (U.S.) in 2023.[1,2] High-risk demographics in the U.S. include young adults (especially ages 20-24), men who have sex with men (MSM), and those identifying as American Indian, Alaskan Native, or Black or African American.[2] Gonorrhea treatment guidelines in the U.S. recommend a 500 mg intramuscular injection with ceftriaxone, but strains resistant to ceftriaxone have spread globally.[3–8] Unlike other common STI pathogens, *N. gonorrhoeae* has evolved resistance to every antibiotic approved to treat it.[9]

Two new first-in-class antibiotics have recently reported positive phase III trial results for gonorrhea treatment: zoliflodacin and gepotidacin.[10,11] Zoliflodacin is a single-dose oral regimen, while the gepotidacin regimen in the phase III study was two oral doses taken 10-12 hours apart. Upon their approval for gonorrhea treatment, recommendations will be required to guide clinical practice.

Modeling studies have examined similar questions about how best to roll out interventions for gonorrhea.[12–14] Most relatedly, one study assessed multiple strategies for introducing one new antibiotic for gonorrhea using a deterministic modeling framework.[12] It found that keeping the new drug in reserve until the currently used therapy reached its resistance prevalence threshold was consistently worse than strategies that deployed the new drug upon approval. Other studies have assessed interventions including point-of-care testing, rapid susceptibility testing, [15–18] vaccination,[13,14,19] screening, and post-exposure prophylaxis.[20–22] No study so far has considered the availability of two new drug options for the treatment of gonorrhea and used a stochastic framework aimed at capturing stochastic resistance emergence and extinction dynamics.

In this study, we compared rollout strategies for two new treatment options in addition to one existing therapy using a stochastic compartmental model of gonorrhea in U.S. MSM. We assessed which rollout strategy maximized the useful lifespan of the three potential treatment options and which combinations of parameters most influenced this result.

METHODS

Model Structure and Implementation

We used a compartmental model of gonorrhea transmission among U.S. MSM adapted from previous studies.[12,15,16,20] Briefly, the model follows susceptible-infected-susceptible (SIS) dynamics. Treatment is successful unless there is resistance to the drug used, in which case treatment fails. We modeled three general drugs, A, B, and C, to represent ceftriaxone, zoliflodacin, and gepotidacin, respectively, acknowledging that the precise parameters (e.g., likelihood of emergence of resistance and fitness cost) for these specific drugs remain unknown.

The population is stratified into high-, medium-, and low-risk, which describe the number of
partnerships formed by individuals in each stratum. Mixing is not fully assortative; partnerships
can be formed within one's own risk stratum and outside of it. All compartments and transitions
between them are shown in **Supplementary Figure 1** and described in **Appendix I & II**.

There are two sets of infected compartments: symptomatic (Y) and asymptomatic (Z).
Symptomatic individuals are assumed to seek treatment, whereas asymptomatic individuals are
only detected and treated at the rate of asymptomatic screening. There is an additional exit rate
from symptomatic compartments representing the possibility of seeking care for retreatment if
symptoms do not resolve after failing treatment. Resistance can occur through two mechanisms
in the model: 1) starting resistance is transmitted, meaning that previously uninfected
individuals are directly infected with resistant bacteria, or 2) people infected with strains that
are susceptible to the antibiotic with which they are treated develop resistance to that
antibiotic. Resistance can only arise to one antibiotic at a time, as infected individuals are
treated with a single antibiotic, though multi-drug resistance can emerge on already resistant
backgrounds.

Transmission, care seeking, screening, natural recovery, and resistance emergence were
modeled as a continuous time Markov chain with event rates (**Appendix II**) matching those of
the deterministic system (**Appendix I**). The system was then simulated in discrete time using
binomial τ-leaping with a time step of one day.[23,24] The implementation of this approach
involved multinomial draws from each compartment at each time step. This stochastic
framework captures rare resistance emergence events and lineage extinctions, which govern
differences in dynamics between different rollout strategies.[25]

The models were implemented in R 4.4.1 using the Odin package[26] and run on the FASRC
Cannon high performance computing cluster at Harvard University. All code used in this project
can be found at: https://github.com/gradlab/MK_twodrugintro_public.

Strategy Comparison

We compared two drug rollout strategies: sequential and equal allocation. In each strategy,
individuals are treated with one drug at a time. At the beginning of the sequential strategy,
everyone is treated with drug A. Once the resistance prevalence threshold is met for drug A, it
phases out and is replaced by B. Once the resistance prevalence threshold is met for drug B, it
phases out and is replaced by C until the end of the simulation. At the beginning of the equal
allocation strategy, each infected individual has a 1/3 chance of being treated with drug A, drug
B, or drug C. Once the first drug hits its resistance prevalence threshold, it is no longer used;
treatment is then either of the two remaining drugs, each with a 1/2 chance. When the
resistance prevalence threshold is met for the second drug, it phases out. The third drug is then
used for the rest of the simulation (**Supplementary Figure 2**)**.**

In both strategies, people with symptomatic infections have a chance to seek retreatment, in
which case they are treated with a last resort treatment that is not drugs A, B, or C, such as
ertapenem.[5] Retreatment is assumed to always be successful. We did not explore combination

therapies because the interactions among the drugs have not been studied in clinical settings
and approval for combination therapy is not being pursued.

The resistance prevalence threshold was set to 5% in the baseline scenario, in keeping with
longstanding guidelines.[27,28] However, we also explored scenarios where the threshold was 1%
or 10%.

Parameter Selection and Sensitivity Analysis

Model parameters were selected by literature search, maximum likelihood estimation
calibration, and sensitivity analysis (**Supplementary Table 1, Supplementary Table 2**).
Parameters were divided into two categories: those governing underlying transmission
dynamics (Group 1), and those relating to drug resistance emergence and persistence (Group 2).
For Group 1 parameters, which were unlikely to affect strategy ordering, we identified starting
values from the literature and calibrated a drug A-only model run for two years using the R
bbmle package as described.[12,29] We then conducted a Latin hypercube sampling (LHS)
sensitivity analysis over all possible values of the calibrated parameters to increase our
confidence in the calibrated parameter values.

We did not calibrate Group 2 parameters and instead performed a broad LHS sensitivity analysis
(**Supplementary Table 2**). These parameters included the probability of resistance emerging on
treatment, the relative transmissibility cost (relative fitness) of drug resistance, and the starting
number of cases of resistance in the system. While these quantities are difficult to ascertain
empirically, we can roughly bound the probability of resistance emerging on treatment using
the substitution rate and observed treatment failures. The *N. gonorrhoeae* substitution rate is
on the order of 10^{-6} substitutions per site per year in magnitude.[30] This is the rate of neutral
mutations that have established, and therefore a lower bound on the order of magnitude for
our model's mutation probability parameter as mutations that are selected are more likely to
establish. While the upper bound is more challenging, a mutation probability of 10^{-4} or above
would mean that there were more than one treatment failures per 10000 cases, which would
amount to at least 60 treatment failures in the US in 2023. To be conservative, we explored
mutation probabilities one order of magnitude outside of what we thought most likely (10^{-3} - 10^{-7}).
167

We used LHS (the lhs package in R[31,32]) for both sensitivity analyses to efficiently and
comprehensively survey a multidimensional parameter space. For each sensitivity analysis, we
generated 1000 unique sets of parameter combinations. For each parameter combination, we
ran 100 stochastic simulations of each strategy.

RESULTS

Baseline Scenario

Models run with the baseline parameter set showed that the equal allocation strategy was
consistently better than the sequential strategy (**Figure 1**). At each time step, the same number
or fewer simulations had met the 5% resistance prevalence threshold to each of the three drugs
under the equal allocation strategy compared to the sequential strategy. By year five, no equal
allocation strategy simulations had met the threshold for any of the drugs, but 61.5% of
sequential strategy simulations had reached 5% resistance prevalence for drug A. By year 10, no
simulations for the equal allocation strategy had met the threshold for any of the drugs, but
99.6% of sequential strategy simulations had reached 5% resistance prevalence for drug A, and
3.5% of sequential strategy simulations had reached 5% resistance prevalence for drug B. After
30 years, 25.2% of equal allocation strategy whereas 100% of sequential strategy simulations
had reached 5% resistance prevalence for drug A, 75.1% of sequential strategy simulations had
reached 5% resistance prevalence for drug B, and 4.0% of sequential strategy simulations had
reached 5% resistance prevalence for drug C.

At every time point, the sequential strategy had lost at least as many of the three available
drugs on average as the equal allocation strategy. At two, five, and 10 years, none of the equal
allocation strategy simulations had lost any drugs whereas by year five, sequential strategy
simulations had lost 0.62 drugs on average (38.5% of simulations lost no drugs, 61.5% of
simulations had lost 1 drug, **Supplementary Table 3**) and by year 10, sequential strategy
simulations had lost an average of 1.03 drugs (0.4% of simulations had lost no drugs, 96.1% of
simulations had lost 1 drug, 3.5% lost 2). By year 30, the equal allocation strategy had lost an
average of 0.25 drugs (74.8% had lost no drugs, 25.2% had lost 1 drug), and the sequential
strategy had lost on average 1.83 (24.9% had lost 1 drug, 71.1% had lost 2 drugs, 4% had lost all
3 drugs, **Supplementary Figure 3**).

Similarly, across the study duration, the sequential strategy had lost all three drugs in the same
or a greater proportion of simulations compared to the equal allocation strategy. On average, a
small proportion of simulations from either strategy had lost all three drugs, but after 50 years,
no equal allocation strategy runs had lost all three drugs compared to 14.0% of sequential
strategy runs (**Supplementary Figure 4**).

The equal allocation strategy also outperformed the sequential strategy at resistance
prevalence thresholds of 1% and 10%, with an equal or greater average number of drugs lost at
each time point in the sequential strategy (**Figure 2**).

Sensitivity analyses

In each of the 1000 Group 1 parameter combinations (**Supplementary Table 1**), the sequential
strategy had lost each drug in an equal or greater proportion of simulations than the equal
allocation strategy (**Supplementary Figure 5**). The results from the sensitivity analysis varying
Group 2 parameters (**Supplementary Table 2**) identified only a small number of scenarios where
more drugs were lost on average in the equal allocation strategy compared to the sequential
strategy. By year 10, simulations from only 22 parameter combinations (2.2% of all
combinations) showed on average more drugs lost under the equal allocation strategy. In each

of these parameter combinations, none of the sequential strategy simulations lost any drugs,
and a maximum of 6% of equal allocation strategy simulations had lost either drug B or drug C
(**Supplementary Table 4, Supplementary Figures 6 & 7**).

After filtering out parameter combinations that included probabilities of resistance emergence
greater than or equal to 10^{-4}, there were 7 parameter combinations where more drugs had
been lost on average under equal allocation than under sequential after 10 years. In each of
these scenarios, only 1-2% of equal allocation simulations had reached 5% resistance
prevalence for either drug B, or drug C, while none of the drug resistance prevalence thresholds
were met in the sequential simulations (**Supplementary Figure 7**). Thus, over nearly all
parameter space, the sequential strategy lost more drugs on average than the equal allocation
strategy.

DISCUSSION

In our modeling study, the equal allocation strategy, in which the two new antibiotics and the
currently used therapy are deployed in equal proportion, randomly across the population
treated, minimized the emergence and spread of antibiotic resistance when compared to a
strategy of rolling out the new drugs sequentially. Under the baseline set of parameters,
resistance to all three treatments was less likely to reach a 5% prevalence threshold in the equal
allocation strategy than in the sequential strategy. This result held at resistance prevalence
thresholds for drug loss of 1% and 10%. Across the simulation period, more drugs on average
were lost due to antimicrobial resistance under the sequential strategy than under the equal
allocation strategy. Our results were robust to a wide range of parameters that alter gonorrhea
transmission dynamics.

The model results were most sensitive to the number of cases of starting resistance, the
probability of resistance emergence, and the relative fitness. Our sensitivity analysis showed
that it was possible to derive parameter combinations where the equal allocation strategy
performed worse than the sequential strategy, but this required extreme and unlikely
combinations of parameter values. Of the 22 parameter combinations where the equal
allocation strategy had lost, on average, more drugs than the sequential strategy by year 10,
only a small proportion of simulations had lost any drugs under equal allocation; a maximum 6%
of simulations had met the 5% prevalence threshold for drug B or drug C. In these scenarios,
drug A never reached its resistance prevalence threshold and therefore drugs B and C were
never used in the sequential strategy; in contrast, their use in the equal allocation strategy
meant that in some scenarios emerging or preexisting resistance to these drugs propagated and
reached the threshold.

We classified the majority of the 22 parameter combinations where equal allocation was worse
into "Class I", where at least one emergence probability was greater than 10^{-4} (**Supplementary**
Figure 6). For example, in one parameter combination, the probability of resistance emerging
on treatment with drug B was 2.86×10^{-4}, which would mean that, for 600,000 cases of
gonorrhea treated with drug B, about 200 would fail treatment, which is an improbably high

treatment failure rate that would likely draw attention. The seven remaining parameter
combinations where the resistance emergence probability for all drugs was less than 10^{-4} (Class
II) required: i) a relatively high number of starting cases of B or C resistance that propagated in
the equal allocation strategy but could not persist in the sequential strategy, ii) a high relative
fitness of B or C resistance (close to 1), and iii) a low enough relative fitness and or resistance
probability for drug A such that the resistance prevalence threshold for drug A was never met
and therefore drugs B and C were never used under the sequential strategy (**Supplementary**
Table 4, Supplementary Figure 7). Even when this occurred, only 1-2% of simulations had
reached the resistance prevalence threshold for drugs B or C after 10 years under the equal
allocation strategy. This emphasizes that the cases where the sequential strategy outperformed
the equal allocation strategy were edge cases involving a co-occurrence of unlikely events.

Several factors not considered in this study may impact rollout decisions. Here, we focused on
an MSM-only sexual network in the U.S., thus these results may not generalize to other sexual
network structures or country settings with higher baseline ceftriaxone resistance prevalences
and different asymptomatic screening practices. Considerations of drug price, availability,
preferences for modes of administration, and toxicities were not included but will be important
drivers of drug use and resistance patterns that will also depend on context.

We modeled a closed system with no importation of drug resistance and did not include the
effects of bystander selection for drug resistance due to antibiotic use for indications outside of
gonorrhea. We assumed that all drug resistance caused treatment failure and did not model
within-individual evolution and variation that may occur along a transmission chain. We fixed
parameter values in each simulation, so that, for example, the relative fitness of a particular
pattern of resistance did not change over time. Our probability of resistance emergence on
treatment broadly referred to any kind of genetic event leading to resistance but did not
differentiate between point mutations or recombination events, which could vary by drug and
have different rates. There is also substantial uncertainty surrounding the parameter values
governing our models. However, we note that our results held across nearly all possible
combinations of the parameter values and form a baseline intuition about drug resistance
dynamics to be expanded upon in the future.

Our framework can be used for further investigations, including evaluating strategies where all
drugs are available, but some are used more than others, the impact of drug synergy and cross
resistance, given that zoliflodacin and gepotidacin target the same molecular complex as
fluoroquinolones, and adaptive strategies that change in response to data on the likelihood of
emergence of resistance and the relative fitness cost of resistance. Alternative screening
strategies could also meaningfully impact resistance minimization; future studies building on
our work could explore expedited partner therapy, rapid gonorrhea tests and rapid
susceptibility testing, and vaccine usage.

In conclusion, introducing two new antimicrobials to treat gonorrhea alongside the currently
used treatment was more effective at minimizing drug resistance than introducing the drugs in
sequence. Our results reinforce that distributing the selective pressures across the population
minimizes the emergence of drug resistance (**Supplementary Figure 8**). This aligns with
deterministic modeling evaluating the introduction of one new treatment for gonorrhea, and

malaria modeling showing that using multiple first-line therapies is beneficial.[12,33] While traditional antimicrobial stewardship emphasizes reserving antibiotics, these results illustrate the importance of disease and context-specific decision-making.

 MAIN FIGURES AND TABLES

Figure 1: Proportion of stochastic simulations reaching the 5% prevalence threshold over time under the equal allocation and sequential strategies. Results from 1000 simulations of each strategy using baseline parameters. A: The proportion of the 1000 simulations of each strategy that have reached the 5% prevalence threshold at each time point. Blues colors show the trajectories for drugs A, B, and C in the sequential strategy, and red colors show the trajectories for drugs A, B, and C in the equal allocation strategy. B: The proportion of the 1000 sequential strategy simulations (blue, left) and the 1000 equal allocation strategy simulations (red, right) that have met the 5% resistance prevalence thresholds for drugs A, B, and C (X-axis) after 2, 5, 10, and 30 years of simulation (Y-axis).

Figure 2: Average drugs lost over time across stochastic simulations by strategy and threshold.
The threshold refers to the prevalence of resistance required to prompt a change in treatment.
In the sequential strategy, once the threshold is met, the drug is no longer used, and a new drug
is phased in. In the equal allocation strategy, the drug is no longer used and the probability of
using the remaining drug or drugs increases. A: Average number of drugs lost across 1000
stochastic simulations of the sequential and equal allocation strategies. Blue lines indicate the
average number of drugs lost across the 1000 sequential strategy simulations, and red lines
indicate the average number of drugs lost across the 1000 equal allocation strategy simulations.
Dotted lines indicate that the threshold for that set of simulations across both strategies was
1%, solid lines indicate a 5% threshold, and dashed lines indicate a 10% threshold. B: The
average number of drugs lost in the sequential strategy (blue, left) and the equal allocation
strategy (red, right) after 2, 5, 10, and 30 years of simulation.

Average # Drugs Lost in the Equal Allocation Strategy vs. the Sequential Strategy

Proportion of Simulations Hitting Threshold in the Equal Allocation vs. Sequential Strategy

Figure 3: Results from sensitivity analysis varying parameters that may influence strategy ordering. Each dot represents one of the 1000 Latin hypercube sampled parameter combinations with 100 simulations run under the sequential strategy and 100 simulations run under the equal allocation strategy. Panels A-C: The X-axis represents the average number of drugs lost across the 100 sequential simulations with that set of parameters, and the Y-axis represents the average number of drugs lost across the 100 equal allocation simulations with that set of parameters at 5 (A), 10 (B), and 20 (C) years. Dots are colored blue if more drugs were lost in the sequential strategy, and red if more drugs were lost in the equal allocation strategy. Insets indicate the percentage of 1000 parameter combinations where more drugs were lost in the equal allocation strategy on average than in the sequential strategy at that time point. Panels D & E: The X-axis represents the proportion of the 100 sequential strategy simulations that had met the resistance prevalence threshold to drug B (panel D) or drug C (panel E), and the Y-axis represents the proportion of the 100 equal allocation strategy simulations that had met the resistance prevalence threshold to drug B (panel D) or drug C (panel E) after 10 years.

ACKNOWLEDGEMENTS

Author Contributions: MCK designed and implemented the study, analyzed the results, and drafted the manuscript. KOR contributed to the design and implementation, supervised the analysis, and edited the manuscript. DH contributed to the implementation and analysis and edited the manuscript. ER contributed to the implementation and edited the manuscript. YHG contributed to the design, conceptualization, and analysis of results, edited the manuscript, and supervised the project. The authors thank all members of the Grad Lab for their valuable feedback on the project, especially QinQin Yu, and thank Jeff Imai-Eaton and Marc Lipsitch for their input.

Funding sources: This work was supported by NIH T32GM007753 (MCK) and R01 AI132606 (YHG), and U.S. Centers for Disease Control and Prevention (CDC) contract 200-2016-91779. These findings and conclusions are the responsibility of the authors and does not necessarily represent the official position of the CDC, National Institute of General Medical Sciences, National Institutes of Health, or other authors' affiliated institutions.

Conflicts of interest: YHG is on the scientific advisory board of Kanso Diagnostics.

REFERENCES

1. WHO Gonorrhoea (Neisseria gonorrhoeae infection). https://www.who.int/news-room/fact-sheets/detail/gonorrhoea-(neisseria-gonorrhoeae-infection).

2. CDC (2024). Sexually Transmitted Infections Surveillance, 2023. STI Statistics. https://www.cdc.gov/sti-statistics/annual/index.html.

3. CDC (2022). Gonococcal Infections Among Adolescents and Adults - STI Treatment Guidelines. https://www.cdc.gov/std/treatment-guidelines/gonorrhea-adults.htm.

4. Eyre, D.W., Town, K., Street, T., Barker, L., Sanderson, N., Cole, M.J., Mohammed, H., Pitt, R., Gobin, M., Irish, C., et al. (2019). Detection in the United Kingdom of the Neisseria gonorrhoeae FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, October to December 2018. Euro Surveill *24*, 1900147. https://doi.org/10.2807/1560-7917.ES.2019.24.10.1900147.

5. Eyre, D.W., Sanderson, N.D., Lord, E., Regisford-Reimmer, N., Chau, K., Barker, L., Morgan, M., Newnham, R., Golparian, D., Unemo, M., et al. (2018). Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018. Eurosurveillance *23*, 1800323. https://doi.org/10.2807/1560-7917.ES.2018.23.27.1800323.

6. Unemo, M., Lahra, M.M., Escher, M., Eremin, S., Cole, M.J., Galarza, P., Ndowa, F., Martin, I., Dillon, J.-A.R., Galas, M., et al. (2021). WHO global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017–18: a retrospective observational study. The Lancet Microbe *2*, e627–e636. https://doi.org/10.1016/S2666-5247(21)00171-3.

7. Hal, S.J. van, Sherry, N., Coombs, G., Mowlaboccus, S., Whiley, D.M., and Lahra, M.M. (2024). Emergence of an extensively drug-resistant Neisseria gonorrhoeae clone. The Lancet Infectious Diseases *24*, e547–e548. https://doi.org/10.1016/S1473-3099(24)00486-9.

8. Reimche, J.L., Pham, C.D., Joseph, S.J., Hutton, S., Cartee, J.C., Ruan, Y., Breaux, M., Ivanof, C., Joshi, A., DeMartino, M., et al. (2024). Novel strain of multidrug non-susceptible Neisseria gonorrhoeae in the USA. The Lancet Infectious Diseases *24*, e149–e151. https://doi.org/10.1016/S1473-3099(23)00785-5.

9. CDC (2024). Drug-Resistant Gonorrhea. Gonorrhea. https://www.cdc.gov/gonorrhea/hcp/drug-resistant/index.html.

10. Ross, J.D.C., Wilson, J., Workowski, K.A., Taylor, S.N., Lewis, D.A., Gatsi, S., Flight, W., Scangarella-Oman, N.E., Jakielaszek, C., Lythgoe, D., et al. (2025). Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study. The Lancet *405*, 1608–1620. https://doi.org/10.1016/S0140-6736(25)00628-2.

439   11.   Luckey, A., Broadhurst, H., Daram, P., Delany-Moretlwe, S., de Vries, J.C., Kittiyaowamarn,
440   R., Lewis, D., Mueller, J.P., Richardson, M.-A., Srinivasan, S., et al. Oral zoliflodacin is non-
441   inferior to a combination of ceftriaxone and azithromycin for treatment of uncomplicated
442   urogenital gonorrhoea: results of a large global Phase 3 randomised controlled trial.

443   12.   Reichert, E., Yaesoubi, R., Rönn, M.M., Gift, T.L., Salomon, J.A., and Grad, Y.H. (2023).
444   Resistance-minimising strategies for introducing a novel antibiotic for gonorrhoea treatment:
445   a mathematical modelling study. The Lancet Microbe *4*, e781–e789.
446   https://doi.org/10.1016/S2666-5247(23)00145-3.

447   13.   Hui, B.B., Padeniya, T.N., Rebuli, N., Gray, R.T., Wood, J.G., Donovan, B., Duan, Q., Guy, R.,
448   Hocking, J.S., Lahra, M.M., et al. (2021). A Gonococcal Vaccine Has the Potential to Rapidly
449   Reduce the Incidence of Neisseria gonorrhoeae Infection Among Urban Men Who Have Sex
450   With Men. J Infect Dis *225*, 983–993. https://doi.org/10.1093/infdis/jiab581.

451   14.   Leng, T., Whittles, L.K., Nikitin, D., and White, P.J. (2025). Modeling gonorrhea
452   vaccination to find optimal targeting strategies that balance impact with cost-effectiveness.
453   npj Vaccines *10*, 128. https://doi.org/10.1038/s41541-025-01159-0.

454   15.   Tuite, A.R., Gift, T.L., Chesson, H.W., Hsu, K., Salomon, J.A., and Grad, Y.H. (2017). Impact
455   of Rapid Susceptibility Testing and Antibiotic Selection Strategy on the Emergence and Spread
456   of Antibiotic Resistance in Gonorrhea. J Infect Dis *216*, 1141–1149.
457   https://doi.org/10.1093/infdis/jix450.

458   16.   Vegvari, C., Grad, Y.H., White, P.J., Didelot, X., Whittles, L.K., Scangarella-Oman, N.E.,
459   Mitrani-Gold, F.S., Dumont, E., Perry, C.R., Gilchrist, K., et al. (2020). Using rapid point-of-care
460   tests to inform antibiotic choice to mitigate drug resistance in gonorrhoea. Euro Surveill *25*,
461   1900210. https://doi.org/10.2807/1560-7917.ES.2020.25.43.1900210.

462   17.   Yaesoubi, R., Xi, Q., Hsu, K., Gift, T.L., St. Cyr, S.B., Rönn, M.M., Salomon, J.A., and Grad,
463   Y.H. (2024). The Impact of Rapid Drug Susceptibility Tests on Gonorrhea Burden and the Life
464   Span of Antibiotic Treatments: A Modeling Study Among Men Who Have Sex With Men in the
465   United States. American Journal of Epidemiology *193*, 17–25.
466   https://doi.org/10.1093/aje/kwad175.

467   18.   Fingerhuth, S.M., Low, N., Bonhoeffer, S., and Althaus, C.L. (2017). Detection of antibiotic
468   resistance is essential for gonorrhoea point-of-care testing: a mathematical modelling study.
469   BMC Med *15*, 142. https://doi.org/10.1186/s12916-017-0881-x.

470   19.   Whittles, L.K., White, P.J., and Didelot, X. (2020). Assessment of the Potential of
471   Vaccination to Combat Antibiotic Resistance in Gonorrhea: A Modeling Analysis to Determine
472   Preferred Product Characteristics. Clin Infect Dis *71*, 1912–1919.
473   https://doi.org/10.1093/cid/ciz1241.

474   20.   Reichert, E., and Grad, Y.H. (2024). Effects of doxycycline post-exposure prophylaxis for
475   prevention of sexually transmitted infections on gonorrhoea prevalence and antimicrobial
476   resistance among men who have sex with men in the USA: a modelling study. The Lancet
477   Microbe *5*. https://doi.org/10.1016/S2666-5247(24)00168-X.

478   21.   Tuite, A.R., Rönn, M.M., Wolf, E.E., Gift, T.L., Chesson, H.W., Berruti, A., Galer, K.,
479   Menzies, N.A., Hsu, K., and Salomon, J.A. (2018). Estimated Impact of Screening on
480   Gonorrhea Epidemiology in the United States: Insights From a Mathematical Model. Sex
481   Transm Dis *45*, 713–722. https://doi.org/10.1097/OLQ.0000000000000876.

482   22.   Tsoumanis, A., Van Dijck, C., Hens, N., and Kenyon, C. (2023). Rethinking Screening
483   Intensity in Terms of Reducing Prevalence or Increasing Selection Pressure for the Emergence
484   of Resistant Gonorrhea: A Modeling Study of Men Who Have Sex With Men in Belgium. Open
485   Forum Infectious Diseases *10*, ofad165. https://doi.org/10.1093/ofid/ofad165.

486   23.   Gillespie, D.T. (2001). Approximate accelerated stochastic simulation of chemically
487   reacting systems. The Journal of Chemical Physics *115*, 1716–1733.
488   https://doi.org/10.1063/1.1378322.

489   24.   Tian, T., and Burrage, K. (2004). Binomial leap methods for simulating stochastic
490   chemical kinetics. J Chem Phys *121*, 10356–10364. https://doi.org/10.1063/1.1810475.

491   25.   Britton, T., and Andersson, H. (2000). Stochastic Epidemic Model and Their Statistical
492   Analysis.

493   26.   FitzJohn, R. (2025). odin: ODE Generation and Integration. (MRC Centre for Global
494   Infectious Disease Analysis).

495   27.   Cyr, S.S. (2020). Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020.
496   MMWR Morb Mortal Wkly Rep *69*. https://doi.org/10.15585/mmwr.mm6950a6.

497   28.   World Health Organization (2012). Global action plan to control the spread and impact
498   of antimicrobial resistance in Neisseria gonorrhoeae. 32.

499   29.   Bolker, B., Team, R.D.C., and Giné-Vázquez, I. (2023). bbmle: Tools for General Maximum
500   Likelihood Estimation. Version 1.0.25.1.

501   30.   Sánchez-Busó, L., Golparian, D., Corander, J., Grad, Y.H., Ohnishi, M., Flemming, R.,
502   Parkhill, J., Bentley, S.D., Unemo, M., and Harris, S.R. (2019). The impact of antimicrobials on
503   gonococcal evolution. Nat Microbiol *4*, 1941–1950. https://doi.org/10.1038/s41564-019-
504   0501-y.

31.   Carnell, R. (2024). lhs: Latin Hypercube Samples. Version 1.2.0.

32.   McKay, M.D., Beckman, R.J., and Conover, W.J. (1979). A Comparison of Three Methods
for Selecting Values of Input Variables in the Analysis of Output from a Computer Code.
Technometrics *21*, 239–245. https://doi.org/10.2307/1268522.

33.   Boni, M.F., Smith, D.L., and Laxminarayan, R. (2008). Benefits of using multiple first-line
therapies against malaria. Proceedings of the National Academy of Sciences *105*, 14216–
14221. https://doi.org/10.1073/pnas.0804628105.

34.   CDC (2024). National Overview of STIs in 2023. STI Statistics. https://www.cdc.gov/sti-
statistics/annual/summary.html.

35.   Barbee, L.A., Dombrowski, J.C., Kerani, R., and Golden, M.R. (2014). Effect of Nucleic Acid
Amplification Testing on Detection of Extragenital Gonorrhea and Chlamydial Infections in
Men Who Have Sex With Men Sexually Transmitted Disease Clinic Patients. Sexually
Transmitted Diseases *41*, 168. https://doi.org/10.1097/OLQ.0000000000000093.

36.   Barbee, L.A., Soge, O.O., Khosropour, C.M., Haglund, M., Yeung, W., Hughes, J., and
Golden, M.R. (2021). The Duration of Pharyngeal Gonorrhea: A Natural History Study. Clin
Infect Dis *73*, 575–582. https://doi.org/10.1093/cid/ciab071.

37.   Barbee, L.A., Khosropour, C.M., Soge, O.O., Hughes, J.P., Haglund, M., Yeung, W., and
Golden, M.R. (2022). The Natural History of Rectal Gonococcal and Chlamydial Infections: The
ExGen Study. Clinical Infectious Diseases *74*, 1549–1556.
https://doi.org/10.1093/cid/ciab680.

38.   de Voux, A., Bernstein, K.T., Kirkcaldy, R.D., Zlotorzynska, M., and Sanchez, T. (2019). Self-
reported extragenital chlamydia and gonorrhea testing in the past 12 months among men
who have sex with men in the United States — American Men's Internet Survey, 2017. Sex
Transm Dis *46*, 563–570. https://doi.org/10.1097/OLQ.0000000000001032.